Work

A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis.

Year: 2005

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: PubMed

Authors: John D Bradley, Alexei A Dmitrienko, Alan J Kivitz, Oscar S Gluck, Arthur L Weaver, Craig Wiesenhutter, Stephen L Myers, Gregory D Sides

Institution: Eli Lilly (United States)

Language: English

Topic: Rheumatoid Arthritis Research and Therapies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2204177528

FWCI: 3.183

Cites:

Cited by: 108

Related to: 10